BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28860708)

  • 1. Onychomadesis associated with chemotherapy: case report and mini literature review.
    Li A; Li Y; Ge L; Li P; Li W
    Drug Des Devel Ther; 2017; 11():2373-2376. PubMed ID: 28860708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel).
    Ghetti E; Piraccini BM; Tosti A
    J Eur Acad Dermatol Venereol; 2003 Jul; 17(4):459-60. PubMed ID: 12834462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bi-weekly nab-paclitaxel and trastuzumab therapy effective against recurrent breast cancer with multiple lung metastases in elderly patient who had previously undergone two chemotherapeutic regimens for treatment of metastatic disease-a case Report].
    Sakurai T; Jinta E; Suzuma T; Yoshimura G; Umemura T; Sakurai T
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1703-6. PubMed ID: 23152023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoleuconychia: A rare reversible entity.
    Sidhu AS; Das L; Singh AS
    Postgrad Med J; 2020 Mar; 96(1133):167. PubMed ID: 31597787
    [No Abstract]   [Full Text] [Related]  

  • 6. [A case of facial nerve palsy induced by nab-paclitaxel].
    Minatani N; Kosaka Y; Sengoku N; Kikuchi M; Nishimiya H; Waraya M; Enomoto T; Tanino H; Watanabe M
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2375-7. PubMed ID: 24394117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
    Chirgwin J; Chua SL
    Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
    Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
    Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
    Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
    Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of nab-paclitaxel 125 mg/m
    Furlanetto J; Jackisch C; Untch M; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Wiebringhaus H; Kümmel S; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Costa SD; Gerber B; Nekljudova V; Loibl S; von Minckwitz G
    Breast Cancer Res Treat; 2017 Jun; 163(3):495-506. PubMed ID: 28315068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A Case of HER2-Positive Breast Cancer Treated with Nipple-Sparing Mastectomywith Immediate Reconstruction Using a Tissue Expander after Nab-Paclitaxel Combined with Chemotherapy].
    Nonomura A; Aomatsu N; Tei S; Haraoka G; Tsujio G; Yamakoshi Y; Wang E; Nagashima D; Hirakawa T; Iwauchi T; Nishii T; Morimoto J; Nakazawa K; Uchima Y; Takeuchi K
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):2056-2058. PubMed ID: 28133220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Case of a Corneal Disorder after Breast Cancer Treatment with Nab-paclitaxel].
    Hosotani Y; Morimatsu T; Takata M; Mimura O
    Nippon Ganka Gakkai Zasshi; 2016 Jun; 120(6):449-53. PubMed ID: 27487717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onychomadesis Following Cutaneous Vasculitis.
    Damevska K; Gocev G; Pollozahani N; Nikolovska S; Neloska L
    Acta Dermatovenerol Croat; 2017 Apr; 25(1):77-79. PubMed ID: 28511755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild Cryotherapy for Prevention of Paclitaxel-Induced Nail Toxicity in Breast Cancer Patients: A Phase II Single-Arm Clinical Trial.
    Mazzega-Fabbro C; Polesel J; Spazzapan S; Meneghetti L; Montagner D; Tabaro G; Bartoletti M; Puglisi F
    Clin Breast Cancer; 2023 Jun; 23(4):447-453. PubMed ID: 36997403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.
    Shigekawa T; Takeuchi H; Misumi M; Matsuura K; Sano H; Fujiuchi N; Okubo K; Osaki A; Aogi K; Saeki T
    Breast Cancer; 2009; 16(1):88-92. PubMed ID: 18478315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation.
    Yorulmaz A; Dogan M; Artuz F; Zengin N
    Cutan Ocul Toxicol; 2017 Jun; 36(2):135-139. PubMed ID: 27086693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
    Kaklamani VG; Siziopikou K; Scholtens D; Lacouture M; Gordon J; Uthe R; Meservey C; Hansen N; Khan SA; Jeruss JS; Bethke K; Cianfrocca M; Rosen S; Von Roenn J; Wayne J; Parimi V; Jovanovic B; Gradishar W
    Breast Cancer Res Treat; 2012 Apr; 132(3):833-42. PubMed ID: 21359953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
    Futamura M; Nagao Y; Ishihara K; Takeuchi M; Nakada T; Kawaguchi Y; Asano M; Kumazawa I; Shiroko T; Morimitsu K; Mori R; Nawa M; Shimokawa T; Yoshida K
    Breast Cancer; 2017 Jul; 24(4):615-623. PubMed ID: 28050738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A patient with primary breast cancer who responded remarkably well to neoadjuvant chemotherapy with FEC100 followed by Abraxane].
    Yoshibayashi H; Ishiguro H; Kawaguchi K; Yamoto M; Nishimura T; Yamada H; Namura M; Nishio N; Nakamura K; Shimada K; Ono K; Kato H
    Gan To Kagaku Ryoho; 2013 May; 40(5):627-9. PubMed ID: 23863587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.